1-苄基-4-氧代哌啶-3-羧酸 | 85277-13-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 中文名称: 1-苄基-4-氧代哌啶-3-羧酸
• 英文名称: 1-Benzyl-4-oxopiperidine-3-carboxylic acid
• CAS: 85277-13-0
• 化学式: C₁₃H₁₅NO₃
• 分子量: 233.26
• InChiKey: VCQNFTHBRZIIOF-UHFFFAOYSA-N

物化性质

• 沸点：
  424.6±45.0 °C(Predicted)
• 密度：
  1.263±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  -0.7
• 重原子数：
  17
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.38
• 拓扑面积：
  57.6
• 氢给体数：
  1
• 氢受体数：
  4

安全信息

• 海关编码：
  2933399090

文献信息

• [EN] GLYCINE METABOLISM MODULATORS AND USES THEREOF<br/>[FR] MODULATEURS DU MÉTABOLISME DE LA GLYCINE ET LEURS UTILISATIONS
  申请人：AGENCY SCIENCE TECH & RES

  公开号：WO2018021977A1

  公开（公告）日：2018-02-01

  The present invention relates to a compound of general formula (I) and/or its solvates, hydrates and pharmaceutically acceptable salts, which are modulators of glycine metabolism. The present invention also relates to the methods for their preparation, pharmaceutical compositions containing these compounds and uses of these compounds in the treatment of disorders/conditions/diseases involving, relating to or associated with glycine metabolism or a pathway where glycine decarboxylase (GLDC, or glycine cleavage system) plays a role. In a preferred embodiment the disorders/conditions/disease is cancer, inflammatory conditions, Alzheimer's disease, metabolic disorders and CNS disorders.

  本发明涉及一般式(I)的化合物及/或其溶剂合物、水合物和药学上可接受的盐，这些化合物是甘氨酸代谢调节剂。本发明还涉及其制备方法、含有这些化合物的药物组合物以及这些化合物在治疗涉及或与甘氨酸代谢或甘氨酸脱羧酶（GLDC，或甘氨酸裂解系统）发挥作用的病症/疾病/疾病的用途。在一个首选实施例中，疾病/疾病是癌症、炎症性疾病、阿尔茨海默病、代谢性疾病和中枢神经系统疾病。
• [EN] USES AND METHODS FOR RECURRENT PRIMARY CNS NEOPLASMS<br/>[FR] UTILISATIONS ET MÉTHODES POUR DES NÉOPLASMES DU SNC PRIMAIRES RÉCURRENTS
  申请人：CHIMERIX INC

  公开号：WO2022241467A1

  公开（公告）日：2022-11-17

  This disclosure relates, at least in part, to a method of treatment. In one embodiment, the method of treatment comprises administering to a subject in need of such treatment at least a first therapeutic agent including ONC-206, 7-benzyl-4-(2,4-difluorobenzyl)-2,4,6,7,8,9-hexahydroimidazo[1,2-a]pyrido[3,4-e]pyrimidin-5(1H)-one, for the treatment of one or more CNS neoplasms.

  本公开涉及至少部分治疗方法。在一种实施例中，治疗方法包括向需要该治疗的受试者施用至少一种第一治疗剂，其中包括ONC-206，7-苄基-4-(2,4-二氟苯基)-2,4,6,7,8,9-六氢咪唑[1,2-a]吡啶[3,4-e]嘧啶-5(1H)-酮，用于治疗一个或多个中枢神经系统肿瘤。
• 7-BENZYL-10-(2-METHYLBENZYL)-2,6,7,8,9,10-HEXAHYDROIMIDAZO[1,2-A]PYRIDO[4,3-D]PYRIMIDIN-5(3H)-ON FOR USE IN THE TREATMENT OF CANCER
  申请人：Oncoceutics, Inc.

  公开号：EP2968294B1

  公开（公告）日：2019-05-01
• 7-BENZYL-4-(2-METHYLBENZYL)-2,4,6,7,8,9-HEXAHYDROIMIDAZO[1,2-A]PYRIDO[3,4-E]PYRIMIDIN-5(1H)-ONE, SALTS THEREOF AND METHODS OF USE
  申请人：Oncoceutics, Inc.

  公开号：EP3068401A1

  公开（公告）日：2016-09-21
• [EN] 7-BENZYL-4-(2-METHYLBENZYL)-2,4,6,7,8,9-HEXAHYDROIMIDAZO[1,2-A]PYRIDO[3,4-E]PYRIMIDIN-5(1H)-ONE<br/>[FR] 7-BENZYL-4-(2-MÉTHYLBENZYL)-2,4,6,7,8,9-HEXAHYDROIMIDAZO[1,2-A]PYRIDO[3,4-E]PYRIMIDIN-5(1H)-ONE
  申请人：ONCOCEUTICS INC

  公开号：WO2015073072A1

  公开（公告）日：2015-05-21

  This disclosure relates, at least in part, to a method of treatment comprising administering to a subject in need of such treatment a first therapeutic agent including 7-benzyl-4-(2-methylbenzyl)-2,4,6,7,8,9-hexahydroimidazo[1,2-a]pyrido[3,4-e]pyrimidin-5(1H)-one, or a pharmaceutically acceptable salt thereof in combination with a second therapeutic agent, wherein the first therapeutic agent and the second therapeutic agent are administered either simultaneously or sequentially.